Covid19

AstraZeneca's Evusheld slashes risk of symptomatic COVID-19 up to 83% | CIDRAP

AstraZeneca's monoclonal antibody combination tixagevimab-cilgavimab (Evusheld) reduced the risk of symptomatic COVID-19 infection by 83% over …

Read more at www.cidrap.umn.edu

Show More

Related Articles

Back to top button